Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.
NCT05155566 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 847
Last updated 2024-01-26
Summary
To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Latin America.
Conditions
- Breast Cancer Metastatic
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-05-15
- Primary Completion
- 2021-03-12
- Completion
- 2021-03-12
Countries
- Argentina
- United Kingdom
Study Locations
More Related Trials
-
RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
NCT04460898 ·Status: COMPLETED
-
A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
NCT03560856 ·Status: UNKNOWN ·Phase: PHASE2
-
Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer
NCT04874025 ·Status: COMPLETED
-
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
NCT02679755 ·Status: COMPLETED ·Phase: PHASE4
-
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
NCT02600923 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
NCT04671615 ·Status: COMPLETED
-
Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe
NCT04109261 ·Status: COMPLETED
-
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)
NCT03809988 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
NCT05399329 ·Status: COMPLETED
-
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
NCT05584644 ·Status: COMPLETED
-
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
NCT02536742 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment After Palbociclib-containing Regimens
NCT04517318 ·Status: COMPLETED
-
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
NCT02756364 ·Status: COMPLETED ·Phase: PHASE2
-
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
NCT06495164 ·Status: ACTIVE_NOT_RECRUITING
-
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344780 ·Status: ACTIVE_NOT_RECRUITING
-
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
NCT04603183 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
NCT02142868 ·Status: NO_LONGER_AVAILABLE
-
A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer
NCT02613208 ·Status: COMPLETED
-
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
NCT05697146 ·Status: ACTIVE_NOT_RECRUITING
-
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
NCT04318223 ·Status: UNKNOWN ·Phase: PHASE2
-
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
NCT05969184 ·Status: UNKNOWN ·Phase: PHASE2
-
Patterns of Prescribing and Monitoring of Palbociclib
NCT03285568 ·Status: COMPLETED
-
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
NCT05132101 ·Status: COMPLETED
-
Palbociclib in Real World Practice
NCT03280303 ·Status: COMPLETED
-
Ibrance Real World Insights
NCT03159195 ·Status: COMPLETED